Primary systemic amyloidosis (PSA), also known as systemic AL amyloidosis, is a condition in which monoclonal immunoglobulin light chains produced by an abnormal plasma cell clone misfold and aggregate into insoluble amyloid fibrils. Per Orphanet, these fibrils deposit throughout multiple organ systems, leading to progressive tissue and organ dysfunction. The condition affects approximately 1 to 5 per 10,000 individuals, according to structured prevalence data. Because the protein responsible for amyloid formation is produced by an abnormal plasma cell clone rather than by a heritable germline variant, no genes are listed in the current structured knowledge packet for this condition, consistent with its acquired plasma cell pathophysiology.

Phenotype data is not included in the current structured knowledge packet for primary systemic amyloidosis, reflecting the heterogeneous nature of organ involvement observed across affected individuals. Per its definition, primary systemic amyloidosis is characterized by multiple organ involvement resulting from the accumulation of amyloid deposits in tissues throughout the body. The specific pattern and severity of manifestations vary considerably among individuals depending on which organ systems are predominantly affected, and clinical presentations span a wide spectrum as documented in the published literature.

Primary systemic amyloidosis arises from the overproduction of abnormal monoclonal immunoglobulin light chains by a plasma cell tumor. These light chains misfold into beta-sheet conformations that aggregate and deposit as amyloid fibrils in organs and tissues throughout the body, causing progressive structural damage. Per the condition's definition, the process is driven by the underlying plasma cell clone rather than by inherited germline genetic variants. No genes appear in the structured knowledge packet for this condition, which is consistent with its acquired plasma cell origin and distinguishes it from hereditary forms of amyloidosis caused by germline mutations in unrelated proteins.

Structured diagnostic criteria are not included in the knowledge packet for primary systemic amyloidosis. Diagnosis in the published clinical literature involves identifying amyloid deposition in affected tissues and confirming the immunoglobulin light-chain origin of the deposits, with the workup shaped by the pattern of organ involvement present in a given case. The specific diagnostic methods and confirmatory steps used in practice reflect an evolving diagnostic landscape and vary by institutional approach, clinical setting, and individual presentation characteristics.

Darzalex Faspro (daratumumab and hyaluronidase-fihj), a combination biologic therapy, holds FDA-approved status for the treatment of light-chain (AL) amyloidosis, as documented in structured orphan drug records for this condition. Beyond this approved agent, a broad range of additional therapeutic strategies targeting the underlying plasma cell clone are under active investigation in ongoing clinical trials. These investigational approaches include antibody-based combination regimens and cellular immunotherapy strategies. No dosing protocols or specific treatment sequencing are included in this summary, as these are determined individually based on clinical factors specific to each case. Treatment planning for this condition characteristically involves a multidisciplinary team with expertise in plasma cell disorders and amyloid-related organ involvement.

Prognosis information is not included in the structured knowledge packet for primary systemic amyloidosis. Published literature indicates that outcomes are shaped by the degree and pattern of organ involvement at the time of diagnosis, the responsiveness of the underlying plasma cell clone to treatment, and the pace of disease progression. Advances in plasma cell-directed therapies documented in the research literature have been associated with evolving outcome data over time. Individual outcomes vary considerably based on the clinical profile of each case.

Primary systemic amyloidosis is the subject of an active and growing research landscape. Per structured research data, more than 170 published studies have been classified for this condition, including a substantial proportion of review articles and meta-analyses, case reports, and trial-based publications. Numerous clinical trials are currently investigating new treatment approaches, including combination regimens incorporating antibody-based therapies, CAR T cell strategies, and other biologics, sponsored by academic medical centers, research networks, and pharmaceutical organizations. Gene therapy-related research publications are also represented in the classified literature for this condition. Information about currently enrolling studies is available through ClinicalTrials.gov.